Home>>Signaling Pathways>> Neuroscience>> Behavioral Neuroscience>>PDE4B Inhibitor

PDE4B Inhibitor (Synonyms: KVA-D-88)

Catalog No.GC47931

A PDE4B inhibitor

Products are for research use only. Not for human use. We do not sell to patients.

PDE4B Inhibitor Chemical Structure

Cas No.: 2410550-31-9

Size Price Stock Qty
1 mg
$77.00
In stock
5 mg
$308.00
In stock
10 mg
$540.00
In stock
25 mg
$1,157.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

PDE4B inhibitor is an inhibitor of phosphodiesterase 4B (PDE4B; IC50 = 140 nM).1,2 It is selective for PDE4B over a panel of 20 PDE isoforms and a panel of 39 CNS receptors at 10 µM but does inhibit the activity of PDE4C1, PDE3B, the serotonin (5-HT) receptor subtype 5-HT2C, and sigma-2 (σ2) receptors by greater than 50%.1 PDE4B inhibitor (1 µM) decreases LPS- or Pam3Cys-induced production of TNF-α in mouse bone marrow-derived macrophages (BMDMs). It reduces cocaine self-administration and the progressive ratio breakpoint in mice when administered at a dose of 5 mg/kg.2

1.Vadukoot, A.K., Sharma, S., Aretz, C.D., et al.Synthesis and SAR studies of 1H-pyrrolo[2,3-b]pyridine-2-carboxamides as phosphodiesterase 4B (PDE4B) inhibitorsACS Med. Chem. Lett.11(10)1848-1854(2020) 2.Burkovetskaya, M.E., Liu, Q., Vadukoot, A.K., et al.KVA-D-88, a novel preferable phosphodiesterase 4B inhibitor, decreases cocaine-mediated reward properties in vivoACS Chem. Neurosci.11(15)2231-2242(2020)

Reviews

Review for PDE4B Inhibitor

Average Rating: 5 ★★★★★ (Based on Reviews and 13 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for PDE4B Inhibitor

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.